TPCA-1

TPCA-1

• CAS Number: 507475-17-4
• UNSPSC Description: TPCA-1 is a potent and selective inhibitor of IKK-2 with IC50 of 17.9 nM. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA binding, and transactivation.
• Target Antigen: Apoptosis; IKK; STAT
• Type: Reference compound
• Related Pathways: Apoptosis;JAK/STAT Signaling;NF-κB;Stem Cell/Wnt
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology; Cancer
• Assay Protocol: https://www.medchemexpress.com/TPCA-1.html
• Purity: 99.72
• Solubility: DMSO : ≥ 100 mg/mL
• Smiles: O=C(C1=C(NC(N)=O)SC(C2=CC=C(F)C=C2)=C1)N
• Molecular Weight: 279.29
• References & Citations: [1]Sachse F, et al. IKK-2 inhibitor TPCA-1 represses nasal epithelial inflammation in vitro.Rhinology. 2011 Jun;49(2):168-73.|[2]Podolin PL, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflamm|[3]Nan J, et al. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers. Mol Cancer Ther. 2014 Mar;13(3):617-29.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported